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late B cells, IL-4 has been found to activate cytotoxic T
cells, modulate macrophage function, and cause B-cell
immunoglobulin class switching.1,2 Our results and the
I nterleukin 4 (IL-4) is primarily a T-lymphocyte andmast cell–derived cytokine with a variety of biologic
functions. Originally described for its ability to stimu-
Objective: The interleukin 4 receptor has been demonstrated on the sur-
face of human non–small cell lung carcinoma cell lines and tumor spec-
imens. Interleukin 4 causes G1-phase cell-cycle arrest of non–small cell
lung cancer cell lines expressing the interleukin 4 receptor; the effect
directly correlates with the expression of the interleukin 4 receptor and
is seen within 48 hours after treatment. We examined signal transduc-
tion pathways used by the interleukin 4 receptor that may account for
growth arrest of the cell line LUst but had no effect on another
non–small cell lung cancer cell line, SK-MES-1. Methods: Western blot
analysis was performed on both LUst and SK-MES-1 cell lines cultured
in the presence of interleukin 4 (500 U/mL). Cells were lysed, protein
extracted, and electroblotted; blots were then probed with murine mono-
clonal antibodies to specific intracellular proteins. Results: Western blot-
ting of the cell lines with antiphosphotyrosine antibody (4G10) demon-
strated multiple (140 kd, 100-130 kd, and 65 kd) phosphoproteins seen
only in the interleukin 4–treated LUst cell line and not observed in the
SK-MES-1 cell lines. Immunoprecipitation and blotting of the LUst cell
line with specific secondary antibodies demonstrated that the 140-kd
phosphoprotein was the interleukin 4 receptor, the 130-kd phosphopro-
tein was Janus kinase 1, the 116-kd phosphoprotein was Janus kinase 3,
and the 65-kd phosphoprotein was the interleukin 2 receptor γ-chain.
Specific binding was not observed in the non–small cell lung cancer cell
line SK-MES-1, suggesting that a functional interleukin receptor γ-
chain was not present. Southern blotting with complementary DNA
probes to interleukin 2 receptor γ-chain confirmed the absence of this
receptor on cell line SK-MES-1. Conclusions: These results suggest that
non–small cell lung cancer cells may express functional cytokine recep-
tors, including the interleukin 2 receptor γ-chain commonly found in
association with the lymphocyte interleukin 2 receptor. These receptors
may be novel targets for directing cytokine-based immune therapy.
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work of other investigators demonstrate that IL-4 can
inhibit growth of a variety of nonhematopoietic malig-
nancies, including melanoma, renal,4 gastric,5 and col-
orectal carcinomas.6 Topp and colleagues7 reported
that IL-4 inhibited the growth of lung carcinoma cell
lines expressing IL-4 receptor (IL-4R) α. Tungekar and
colleagues8 demonstrated the presence of IL-4R on
35% of fresh surgical specimens of human squamous
and adenocarcinoma lung cancers and found that the
effect of IL-4 was mediated through its receptor. We
have previously demonstrated that IL-4 produces
G0/G1 cell-cycle arrest of IL-4R+ cell lines.9 Yet the
molecular mechanisms that regulate the downstream
processing of the IL-4 signal in nonhematopoietic cells
are not well understood.
The complementary (c)DNA for the human IL-4Rα
has been cloned, is well characterized, and is part of the
hematopoietic superfamily of receptors.10 Crosslinking
studies demonstrate that IL-4 binds to the high-affinity
140-kd IL-4Rα and 65-kd IL-2R γ-chain in hematopoi-
etic cells,11 although this process has not been demon-
strated in nonhematopoietic malignancies. The intra-
cellular domains of the IL-4Rα have no consensus
sequences for tyrosine or serine-threonine kinases,
although tyrosine phosphorylation (170-kd, 140-kd,
and 110-kd proteins) has been observed after IL-4 acti-
vation of murine lymphoid cell lines.12 These studies
suggest the 140-kd protein is the IL-4Rα, and this pro-
tein activates both the 170-kd insulin receptor substrate
1 (IRS-1), the Janus kinase (JAK) family of transcrip-
tion factors, and the signal transducers and activators of
transcription (STAT) 6.12,13 In the current investigation
we examined the growth-inhibitory effects of IL-4 on 2
human non–small cell lung carcinoma (NSCLC) cell
lines. Our data indicate that the IL-4–responsive
NSCLC cell line LUst demonstrated growth inhibition
in the presence of IL-4 with tyrosine phosphorylation
of multiple proteins. Although IRS-1 is constitutively
expressed in both the LUst and SK-MES-1 cell lines,
immunoprecipitation of the IL-2R γ-chain along with
IL-4Rα in the LUst cell line suggests that this receptor
complex is necessary for activation of JAK1 and JAK3,
along with STAT6. The absence of IL-2R γ-chain in the
nonresponsive cell line SK-MES-1 may explain the
inability of this cell line to respond to IL-4 and be use-
ful for the design of therapies directed at IL-4R+ lung
cancers.
Methods
Cell lines. Human NSCLC cell lines LUst (established at
the University of California, Los Angeles, gift of G. Juillard)
and SK-MES-1 (American Type Cell Culture, Rockville, Md)
were cultured in RPMI-1640 culture medium (JRH
Biosciences, Lenexa, Kan) or Dulbecco’s modified Eagle’s
medium (Life Technologies Inc, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal calf serum (Gemini
Bioproducts, Calabasas, Calif) and antibiotics (100 U/mL
each of penicillin and streptomycin) in 75-cm2 flasks. The
human gastric cancer cell line CRL 1739 (ATCC) and colon
carcinoma line (Spiro or CoSp) established at our laboratory
served as positive controls in some studies because they have
shown growth inhibition in the presence of IL-4. All cell cul-
tures were maintained in continuous exponential growth by
weekly passage, as previously described.5
Cytokines and reagents. Recombinant human IL-4 (1.8 ×
107 U/mg) was the generous gift of Schering Plough
(Kenilworth, NJ). Mouse monoclonal IgG2b antiphosphoty-
rosine (clone 4G10), agarose-conjugated antiphosphotyro-
sine 4G10 antibody, IgG anti-JAK1, and anti-IRS-1 antibod-
ies were obtained from Upstate Biotechnology (Lake Placid,
NY). Rabbit polyclonal IgG anti-IL-4Rα, anti-IL-4 Stat
(STAT6), anti-IL-2R γ-chain, and anti-JAK3 antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
Calif). Anti-IL-2R γ-chain monoclonal antibody was a kind
gift of Dr K. Sugamura (Tohoku University School of
Medicine, Sendai, Japan).
RNA extraction. Total cellular RNA was extracted by
using the UltraSpec isolation system (Biotecx, Houston,
Tex), as described by the manufacturer. Briefly, cells were
trypsinized, washed in 1× phosphate-buffered saline (PBS),
lysed in 2 mL of UltraSpec reagent by repetitive pipetting,
and placed on ice for 5 minutes in an RNAse-free Eppendorf
tube. Four hundred microliters of chloroform was added, and
after vigorous mixing for 15 minutes, the solution was placed
on ice for 5 minutes and then centrifuged at 12,000g at 4°C
for 15 minutes. The aqueous phase was transferred into
another RNAse-free Eppendorf tube; one volume of iso-
propanol was added, and the solution was precipitated at 4°C
for 30 minutes. The tube was centrifuged at 12,000g at 4°C
for 20 minutes to obtain an RNA pellet. The sample was
washed with 70% ethanol, dried, and resuspended in 50 µL
of diethyl pyrocarbonate–treated TRIS-hydroxymethyl-
amino methane (TRIS)-ethylenediamine tetraacetic acid
(EDTA) buffer. All RNA extraction procedures were per-
formed in a designated laminar flow hood under sterile con-
ditions. Polymerase chain reaction (PCR) reagent set-up and
gel electrophoresis were performed in separate rooms to
avoid potential RNA contamination.
Reverse transcription PCR. Total sample RNA was
reverse transcribed by using the reverse transcription (RT)
mixture consisting of Moloney murine leukemia virus reverse
transcriptase with oligo (dT) primer, as previously de-
scribed.5 Three micrograms of sample RNA was used in the
reactions. All reagents were obtained from Promega
(Madison, Wis). The reaction was incubated at 37°C for 2
hours, at 99°C for 5 minutes, and on ice for 5 minutes.
PCR amplification. Oligonucleotide primers were synthe-
sized and purified by Gibco BRL (Gaithersburg, Md).
Oligonucleotide 5´ and 3´ primers for individual genes were
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designed as follows: IL-2R γ-chain, 5´-GGCCACACAGAT-
GCTAAAACT-3´ and 3´-GAACAATGACTTATGGTGCCC-
5´; IL-4Rα, 5´-ATGGGGTGGCTTTGCTCTGGG-3´ and
3´-ACCTTCCCGAGGAAGTTCGGG-5´; and β-actin-
5´CCTTCCTGGGCATGGAGTCCTG-3´ and 3´-CTTC-
TAGTTCTAGTAACGAGG-5´. The PCR cDNA products of
IL-2R γ-chain, IL-4Rα, and β-actin were 492 bp, 345 bp, and
202 bp, respectively. The PCR was performed as previously
described.5 The annealing temperature for primers was
designed by using OLIGO Primer Analysis Software 5.0
(Plymouth, Minn), and the PCR conditions were set up as fol-
lows: 95°C for 5 minutes followed by the cycle of 95°C for 1
minute, 67°C for IL-2R γ-chain (64°C for IL-4Rα and 55°C
for β-actin) for 1 minute, and 72°C for 1 minute, with a repeat
of the three 1-minute phases for 35 cycles and a final 72°C
for a 10-minute extension time and final soaking at 4°C. The
PCR reaction was performed in an OmniGene temperature
cycler (Hybaid, Middlesex, England). The preparation of
PCR mixture for the temperature cycler was performed in a
designated PCR room in a sterile laminar flow hood. 
The PCR cDNA product was detected by electrophoresis
on a 2% agarose gel (Life Technologies Inc) and visualized
by ethidium bromide staining under UV light. A 100-bp DNA
ladder (Life Technologies Inc) was used as a reference mark-
er for all assays. 
Southern blot analyses. After electrophoresis of PCR
cDNA products, agarose gels were transferred overnight onto
nitrocellulose membranes (Scheicher and Schull, Keene, NH)
with 20× standard sodium citrate (SSC) buffer (1× SSC =
0.15 mol/L sodium chloride plus 0.015 mol/L sodium cit-
rate), as previously described,14 and UV cross-linked at 1200
mJ/cm2 by using a UV Crosslinker (Fisher Scientific,
Pittsburgh, Pa). The cDNA probe was prepared from PCR
cDNA product of the IL-2R γ-chain sequence inside the
PCR primers. The probe was prepared and labeled by using
the DIG DNA Labeling Kit (Boehringer Mannheim,
Indianapolis, Ind) according to the manufacture’s protocol.
The template cDNA was heat denatured before random
primer labeling. The labeling reaction resulted in incorpora-
tion of DIG-dUTP (uracil triphosphate) every 20 to 25
nucleotides in the newly synthesized DNA probe. Labeled
DNA was precipitated with 4 mol/L lithium chloride and
70% ethanol. The blot was prehybridized, and the labeled
cDNA was added to the blot in hybridization solution (5×
SSC, blocking reagent, 0.1% N-lauroylsarcosine, and 0.02%
sodium dodecylsulfate [SDS]) at the concentration of 26
ng/mL and hybridized overnight at 68°C. Specific binding
was detected by using the DIG Nucleic Acid Detection Kit
(Boehringer Mannheim). After hybridization to target DNA,
the hybrids were detected by using an enzyme-linked
immunoassay with the antidigoxigenin-alkaline phosphatase
conjugate and subsequent enzyme-catalyzed color reaction
with 5-bromo-4-chloro-3-indolyl phosphatase and nitro blue
tetrazolium salt at room temperature until the desired bands
were detected. The reaction was terminated by washing the
blot for 5 minutes in 10 mmol/L TRIS-HCl and 1 mmol/L
EDTA (pH 8.0). The results were documented by photograph.
Flow cytometry. Flow cytometric examination of IL-4Rα
expression on the cell surface was performed with biotin-
labeled IL-4, as described previously.5 Briefly, biotin-N-
hydroxysuccinimide (Calbiochem, La Jolla, Calif) and purified
rhIL-4 were mixed at molar ratios. This mixture was incubated
at room temperature for 30 minutes and mixed every 10 min-
utes during incubation. The reaction mixture was then dialyzed
in PBS and adjusted to 10 µg/mL in PBS plus 0.01% NaN3.
Tumor cells (5 × 105) were incubated with 50 ng of biotinyl-
ated IL-4 in 100 µL of PBS plus 0.02% NaN3 plus 2% heat-
ed-inactivated fetal calf serum for 30 minutes at 4°C. After 3
washes with PBS-NaN3, the cells were further incubated in
50 µL of diluted streptavidin-fluorescein isothiocyanate for
30 minutes at 4°C. Cells were washed 3 times and analyzed
by FACScan (Becton-Dickinson, Mountain View, Calif).
Peripheral blood lymphocytes (PBLs) were obtained from
normal healthy donors and activated with 0.5 µg/mL phyto-
hemagglutinin (Sigma Chemical Corp, St Louis, Mo) plus
IL-2 for 48 hours in culture. These activated PBL cultures
were used as a positive control for IL-4Rα analysis.
Cell proliferation. A standard tritiated-thymidine (New
England Nuclear, Boston, Mass) incorporation proliferation
assay was set up in 96-well, round-bottom microplates
(Costar, Cambridge, Mass).15 NSCLC cell lines were seeded
in the wells at a concentration of 104 cells per well in 200 µL
of culture medium in the presence or absence of IL-4. Each
test was performed in triplicate. Cells were cultured for 48
hours and pulsed with tritiated thymidine for 6 hours before
harvesting. Microplate wells were harvested by using a
Brandel harvester (Brandel, Gaithersburg, Md) and counted
in a Beckman scintillation counter (Beckman, Fullerton,
Calif), as previously described.5,15
Immunoprecipitation and immunoblot analysis. Cell
lines were washed and then incubated in serum-free medium
1 night before adding cytokine. After stimulation with IL-4
(500 U/mL) for approximately 10 minutes at 37°C, the cells
were lysed in lysis buffer (10 mmol/L TRIS-HCl [pH 7.2],
150 mmol/L sodium chloride, 1% sodium deoxycholate, 5
mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 20
mmol/L sodium fluoride, 100 µmol/L sodium vanadate, 10
µg/mL leupetin, and aprotinin; Sigma Chemical Co). The
lysates were centrifuged at 12,000g for 20 minutes at 4°C to
remove insoluble material. The total protein content of the
lysates was determined by using the Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, Calif). Equal amounts of
clarified cell lysates (approximately 2 mg) were immunopre-
cipitated with 3 µg of anti-IL-2R γ-chain (Santa Cruz
Biotechnology) or monoclonal antiphosphotyrosine antibody
(4G10; Upstate Biotechnology) by using 20 µL of protein A
insolubilized on Sepharose 4B fast flow (Sigma Chemical
Co). The immunoprecipitates were washed twice in dilution
buffer (0.1% Triton X-100 and bovine hemoglobin in TSA
solution [0.01 mol/L TRIS-Cl, pH 8.0; 0.14 mol/L sodium
chloride; and 0.025% sodium azide]) one time in TSA solu-
tion and another in 0.05 mol/L TRIS-Cl (pH 6.8) solution sol-
ubilized with Laemmli buffer, boiled, and resolved by TRIS-
glycine 4% to 12% SDS-polyacrylamide gel electrophoresis
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(Novex, San Diego, Calif). In some experiments proteins (75
µg) were directly resolved by SDS-polyacrylamide gel elec-
trophoresis without prior immunoprecipitation.
Western blot analyses were performed by transferring pro-
teins from polyacrylamide gels onto Hybond-ECL nitrocellu-
lose membranes (Amersham Corp, Arlington Heights, Ill) at
25 V for 2 hours in TRIS-glycine buffer containing 25
mmol/L TRIS, 192 mmol/L glycine, 0.1% SDS, 100 µmol/L
sodium vanadate, and 20% methanol. The blots were treated
for 1 hour with blocking buffer (2.5% nonfat dry milk, 10
mmol/L TRIS-Cl [pH 7.5], 100 mmol/L sodium chloride, and
0.1% Tween 20) and then incubated with 2 µg/mL antibody
in blocking buffer for another hour. Antibody binding was
detected by incubating the blots for 1 hour with sheep anti-
mouse or anti-rabbit immunoglobulin conjugated with horse-
radish peroxidase, followed by a 1-minute incubation with
iodinated substrate and then enhanced chemiluminescence
detection (ECL; Amersham Corp, Arlington Heights, Ill). The
blots were exposed to autoradiography film (Hyperfilm-
ECL). Some blots were reprobed after being stripped with 2%
SDS, 6.25 mmol/L TRIS (pH 6.7), and 100 mmol/L 2-mer-
captoethanol at 55°C for 30 minutes with gentle agitation.
Relative differences in protein expression were determined
through densitometry by using a dual-wavelength flying-spot
scanner (Shimadzu Corp, Kyoto, Japan).
Statistics. Differences in means and SDs for growth analy-
ses were performed by using the sign test with the nonpara-
metric t test.
Results
Effect of IL-4 on cell growth. Because IL-4 has
been implicated as having growth-inhibitory effects on
human nonhematopoietic cell lines and, in particular,
lung carcinoma cells, we examined the mechanisms of
its action on the 2 NSCLC lines, LUst and SK-MES-1.
IL-4 (100-500 U/mL) significantly (P = .0001) inhibit-
ed the growth of LUst in 48-hour culture compared
with untreated LUst (Fig 1). Growth inhibition was
dose dependent and was seen with as little as 100 U/mL
IL-4. Maximal inhibition of growth (68% ± 5%) was
Fig 1. Effects of IL-4 on growth of 2 NSCLC lines, LUst and
SK-MES-1. Cells were cultured for 48 hours in the presence
or absence of IL-4. Growth inhibition was determined by per-
centage inhibition of tritiated thymidine incorporation.
Values are means ± SDs and demonstrate significant (P =
.0001; sign test, nonparametric t test) growth inhibition
induced by IL-4 for cell line LUst versus untreated cell line
(untreated LUst, 11,204 ± 175 cpm). IL-4 had no effect on
tritiated thymidine incorporation of SK-MES-1 (untreated
SK-MES-1, 34,299 ± 5702 cpm). Representative experiments
were performed in triplicate.
Fig 2. Western blot analysis demonstrating specific binding
of the 140-kd IL-4Rα. The 2 NSCLC cell lines, SK-MES-1
and LUst, were treated for up to 30 minutes in the presence
of 500 U/mL of rhIL-4. Western blots were performed from
cell lysates by using antibody to IL-4Rα (see “Methods” sec-
tion). The human colon carcinoma cell line Spiro (CoSp)
established in our laboratory has previously been found to
express a high level of IL-4Rα and served as positive control
for this experiment.25
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observed with 500 U/mL IL-4. Higher concentrations
of IL-4 (>500 U/mL) had no further effect on growth
inhibition in LUst (data not shown). These findings of
a maximal dose effect by IL-4 have been observed by
other investigators. Cultured cells were noted to
become wider and fattened but remained adherent to
plastic plates in response to IL-4. Exchanging the cul-
ture supernatant with IL-4–free culture medium 24
hours after the experiment was initiated did not reverse
the effect of IL-4. Previous work by our laboratory sug-
gests IL-4 causes G0/G1 cell cycle-phase arrest of IL-
4–responsive lines.5,9 Trypan blue exclusion demon-
strated that IL-4 was not toxic to the cell lines, and the
concentrations were accordingly well below the report-
ed level of toxicity for B and T cells in vitro.16 The SK-
MES-1 cell line was nonresponsive to the growth-
inhibitory effects of IL-4 at all of the concentrations
used for LUst.
Fig 3. Flow cytometric analysis of IL-4Rα expression. Both LUst and SK-MES-1 cell lines were subjected to
flow cytometric analysis by using biotin-labeled human rhIL-4 (see “Methods” section). SK-MES-1 was found
not to express IL-4Rα (A), whereas 70% of LUst cells were found to express IL-4Rα (B). PHA- and IL-2–stim-
ulated PBLs served as positive controls for IL-4Rα expression in this experiment.
Fig 4. IL-4Rα and IL-2R γ-chain mRNA expression from LUst and SK-MES-1 cell lines. Both LUst and SK-
MES-1 cell lines were assessed by RT-PCR to determine expression of IL-4Rα and IL-2R γ-chain. The 345-bp
IL-4Rα was expressed by both LUst and SK-MES-1 cell lines. The 492-bp IL-2R γ-chain product was expressed
by the LUst but not by the SK-MES-1 cell line. Southern blotting confirmed the RT-PCR product was IL-2R γ-
chain (see “Methods” section).
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Expression of IL-4Rα. Western blot and flow
cytometry analyses were performed to determine the
expression of IL-4Rα on our 2 cell lines. Western blot
analyses with specific antibodies to IL-4Rα demon-
strated evidence of the 140-kd IL-4Rα in LUst and in a
colon carcinoma cell line, Spiro (CoSp), we established
in our laboratory,17 whereas SK-MES-1 had only min-
imal expression of the IL-4Rα (Fig 2). Flow cytometry
experiments demonstrated binding of biotinylated
rhIL-4 to IL4Rα–positive LUst and no binding to SK-
MES-1 (Fig 3). The discrepancy between the Western
blot and flow cytometric results may be explained by
the difference in sensitivity of the 2 assays and the pos-
sibility of differences in function of the cell surface IL-
4Rα and expression from cell lysates on the responsive
and nonresponsive cell lines. Human PBLs stimulated
with IL-2 served as positive controls for the flow
cytometry experiments (data not shown).
Expression of IL-2 R γ-chain. We performed RT-
PCR analyses of the 2 cell lines to determine whether
IL-4 binding to our 2 cell lines related to messenger
(m)RNA expression of either IL-4Rα or IL-2R γ-chain.
The 345-bp IL-4Rα product was present in both LUst
and SK-MES-1, confirming the findings obtained by
Western blotting. The lack of IL-4 binding by SK-
MES-1 may be indicative of a quantitative difference in
cell surface expression or posttranslational modifica-
tion of the IL-4Rα product (Fig 4).
The IL-2R γ-chain has been found to be an important
component of IL-2 binding in hematopoietic cells and
recently has been shown to be essential for signal trans-
duction of a variety of cytokines, including IL-4.13-18
We assessed IL-2R γ-chain mRNA expression by RT-
PCR to determine its relationship to IL-4 binding in our
2 NSCLC cell lines. The 492-bp IL-2R γ-chain was
found in untreated LUst and human PBL control cells
but was absent in SK-MES-1. Southern blot analyses
confirmed that the 492-bp RT-PCR cDNA products
found from both the human PBLs and LUst cell line
were IL-2R γ-chain products.
Fig 5. Tyrosine phosphorylation of IL-4–treated and –untreated NSCLC cell lines. Both human NSCLC cell lines
were cultured in serum-free medium overnight and then treated with 500 U/mL IL-4 for 10 minutes. A, Western
blotting with antiphosphotyrosine antibody (4G10) demonstrated 140-kd and 65-kd phosphoproteins in IL-
4–treated LUst not present in SK-MES-1. B, Immunoprecipitation with antiphosphotyrosine (4G10) and blotting
with anti-IRS-1 demonstrated specific expression of IRS-1 from both cell lines. PTyr, Phosphotyrosine.
16 Essner et al The Journal of Thoracic and
Cardiovascular Surgery
January 2000
Tyrosine phosphorylation response to IL-4. Because
the LUst cell line was found to express both IL-4Rα and
IL-2R γ-chain, we sought to determine whether the signal
transduction pathways known to be essential for
hematopoietic cells (by means of IRS-1 or JAK-STAT)
would be important for IL-4–induced growth inhibition
in the LUst cell line. Western blot of the IL-4–treated
LUst cell line with the mouse monoclonal antiphospho-
tyrosine (4G10) demonstrated tyrosine phosphorylation
of 140-kd and 65-kd proteins in the IL-4–treated LUst
cell line that were not present from untreated cells (Fig 5,
A). Analysis of SK-MES-1 cell lysates from IL-4–treated
and –untreated lines demonstrated no specific protein
patterns in the presence of IL-4.
The IL-4Rα has been found to signal through IRS-1–
dependent pathways in both hematopoietic and non-
hematopoietic cell lines.19 We observed no evidence of
the 170-kd IRS-1 phosphoprotein by using Western
blotting with 4G10 antibody or specific binding with
anti-IRS-1 antibody (data not shown). When the cell
lines were immunoprecipitated with 4G10 and blotted
with anti-IRS-1 antibody, we found that both cell lines
expressed almost equal quantities of IRS-1 protein (Fig
5, B). There was no enhancement in IRS-1 protein
expression (gel films assessed by densitometry) after
treatment with IL-4 for 10 minutes or up to 1 hour, sug-
gesting that IRS-1 is likely not involved in IL-
4–induced growth inhibition of the LUst cell line.
Phosphorylation of the IL-2R γ-chain. Because our
earlier experiments demonstrated the presence of IL-
2R γ-chain in the LUst cell line, we examined for the
presence of the secondary messengers known to be
associated with IL-2R γ-chain binding. Immuno-
precipitation with anti-IL-2R γ-chain antibody and
blotting with 4G10 antibody demonstrated multiple (65
kd, 140 kd, 130 kd, and 116 kd) phosphoproteins from
the IL-4–treated LUst cell line (Fig 6). The 130- and
116-kd phosphoproteins were not observed by using
Western blotting with antibody 4G10 alone, which we
suspect to be because of the high level of background
phosphoproteins seen by blotting with 4G10 alone (Fig
2). SK-MES-1 failed to demonstrate any significant
binding of the IL-2R γ-chain antibodies, suggesting
that the IL-4Rα/IL-2R γ-chain complex was necessary
for phosphorylation of the multiple secondary messen-
gers. We reblotted the membranes with anti-IL-2R γ-
chain and anti-IL-4Rα antibodies, demonstrating that
both the IL-4Rα and IL-2R γ-chain products are pre-
sent and interact in the IL-4–treated LUst cell line.
Phosphorylation of JAK. JAK3 and JAK1 have
been shown to be an important part of IL-4 signal trans-
duction in hematopoietic cells.20 The 116-kd JAK3
Fig 6. IL-2R γ-chain expression in NSCLC cell line LUst. The cell line LUst was cultured in serum-free medium
overnight and then treated with 500 U/mL IL-4 for 10 minutes. Cell lysates were immunoprecipitated with anti-
IL-2R γ-chain antibody and probed with specific antibodies to antiphosphotyrosine, IL-2R γ-chain (65 kd), IL-
4Rα (140 kd), JAK1 (130 kd), and JAK3 (116 kd). PTyr, Phosphotyrosine.
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protein has been found to associate with IL-2R γ-chain
in nonhematopoietic cells and serves as an activator of
the JAK-STAT pathway. We performed immunoprecip-
itation of cell lysates with anti-IL-2R γ-chain antibody
and probed with anti-JAK3 antibodies. Western blot-
ting with anti-JAK3 antibody demonstrated slight
enhancement in quantitative binding (determined by
densitometry of the blot films) between IL-4–treated
and –untreated LUst cell lines (and control cell lines
CRL1739 and Spiro; Fig 7). Similar results were
observed when blots were reprobed for the 130-kd
JAK1. JAK1 binds to the IL-4 receptor and complexes
with the IL-2R γ-chain. The IL-4–responsive LUst cell
line demonstrated activation of JAK1 (Fig 8). We
attempted to examine the response of the STAT6 pro-
tein in the IL-4–sensitive LUst cell line. Western blots
demonstrated the presence of the 100-kd STAT6 (IL-4
Stat), but no quantitative differences were seen in the
presence of IL-4, whereas SK-MES-1 cell lysates
demonstrated no binding to the anti-STAT6 antibody
(data not shown). These results suggest that the IL-
4Rα/IL-2R γ-chain complex binds to JAK-dependent
pathways after activation with IL-4.21,22
Discussion
Our results demonstrate that rhIL-4 inhibited the
growth of a human NSCLC cell line, and the effect was
directly related to the expression of IL-4Rα. A second
NSCLC cell line, SK-MES-1, demonstrated only mini-
mal expression of IL-4Rα and was unresponsive to the
growth-inhibitory effect of IL-4. The 140-kd IL-4Rα
has been well characterized and has been found on a
number of human nonhematopoietic cell lines.
Although we did not quantitate the number of IL-4Rα
molecules present on these 2 cell lines, other investiga-
tors have found anywhere from 2000 to 6000 IL-4Rα
molecules per cell on responsive cell lines.4-6 The min-
imum number of IL-4Rα molecules for IL-4 to inhibit
cell growth is unknown.
We believe that IL-4–induced growth inhibition of
the LUst cell line is directly mediated by IL-4Rα. LUst
cells were sensitive to the effects of IL-4 and had a high
level (>60%) of receptor expression, as demonstrated
by flow cytometry binding with a biotinylated rhIL-4.
SK-MES-1 expressed minimal levels of IL-4Rα by
Western blotting (using specific antibody to IL-4Rα),
but our flow cytometry data indicate no functional
binding with biotinylated IL-4. IL-4 had no effect on
cell proliferation of SK-MES-1. We performed RT-
PCR analyses of these 2 cell lines by using specific
oligonucleotide primers that verify the presence of IL-
4Rα mRNA in the LUst and SK-MES-1 cell lines. The
SK-MES-1 cell line constitutively expressed low levels
of IL-4Rα mRNA, suggesting that possible posttran-
scriptional modification of the receptor or poor protein
expression may be responsible for the inactivity of the
receptor. Monoclonal antibody (M57) to IL-4Rα
blocks the growth inhibition induced by IL-4 on the
LUst cell line, suggesting that the effect of IL-4 is
mediated through IL-4Rα but does not exclude the pos-
sibility that IL-4 works through the activation of other
secondary cytostatic factors.4
We identified a 65-kd phosphoprotein that is present
in the rhIL-4–treated LUst cell line but not present in
the SK-MES-1 cell line. Our data suggests that this 65-
kd species is the IL-2R γ-chain. Although the IL-2R γ-
chain is more commonly associated with IL-4 (and IL-
2, IL-7, and IL-13) binding in hematopoietic cells,
these results suggest that the IL-2R γ-chain is present in
an established IL-4Rα+ human NSCLC cell line. Our
studies (unpublished observation, 1998) and a report
from another group of investigators23 have also
observed the presence of IL-2R γ-chain in other human
nonhematopoietic cell lines (gastric and colon cancers)
and tumor biopsy specimens. Other investigators have
observed a 70-kd product from IL-4–treated non-
hematopoietic cells and have suggested that this pro-
tein may represent degradation products of the 140-kd
IL-4Rα24 or may represent an alternative binding pro-
tein, as seen in IL-13 binding.19,25 IL-13 had no effect
on the growth of either of our cell lines. Specific bind-
ing demonstrated by immunoprecipitation studies and
confirmation by Southern blotting has found that the
65-kd protein in the NSCLC cell line, LUst, is the IL-
2R γ-chain.
To understand the mechanisms of IL-4–induced inhi-
Fig 7. JAK3 expression from NSCLC cell line LUst. Western
blotting of the LUst cell line after immunoprecipitation by
anti-IL-2R γ-chain antibody and blotting with specific anti-
JAK3 antibody demonstrated JAK3 expression from untreat-
ed and IL-4–treated LUst cell line. The IL-4–responsive cell
lines CRL1739 and Spiro served as controls.
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bition of tumor cell growth inhibition, we investigated
the signal transduction pathways used by IL-4 in the
NSCLC cell line LUst. IL-4 signaling events appear to
act through the IL-4Rα and JAK-STAT pathways used
by hematopoietic cells. Several studies have shown that
an alternative pathway exists in which the secondary
messenger IRS-1 is phosphorylated in response to IL-
4.26 Yet it has been suggested that the phosphorylation
of IRS-1 may occur only in the presence of IL-2R γ-
chain.27 Our results suggest that although IRS-1 was
expressed in both IL-4–responsive and –nonresponsive
cell lines, the level of expression was no different in the
2 cell lines and likely excludes the possibility of IRS-1
contributing to IL-4–induced growth arrest.24 Because
JAK and IRS-1 have been found to associate with the
140-kd IL-4Rα in murine T cells, it is possible that
JAK phosphorylates IRS-1 without involving the IL-2R
γ-chain.28
After complexing of IL-4Rα and IL-2R γ-chain in
hematopoietic cells, several investigators have demon-
strated activation of both JAK1 and JAK3.21,22 Ligand
binding to IL-4Rα has been shown to activate associat-
ed JAK tyrosine kinases, which phosphorylate each
other, as well as receptor tyrosine phosphoproteins.
Several investigators have demonstrated that IL-2R γ-
chain complexes with JAK3 after activation with IL-2
or IL-4.20,21,29 Our results confirm these results in the
NSCLC cell line LUst, and the lack of growth inhibi-
tion observed in other nonhematopoietic cell lines may
result from the absence of IL-2R γ-chain and JAK
interactions. Recent studies demonstrate that STAT6 is
recruited to the activated IL-4Rα by docking of the
SH2 domain where they are phosphorylated by JAKs
and then dimerize and translocate to the cell nucleus
where gene activation occurs.21,22,24 Our work is the
first to our knowledge to describe complexing of IL-
4Rα and IL-2R γ-chain in nonhematopoietic cells
along with expression of JAK1, JAK3, and STAT6.
It is clear that IL-4 has contrasting effects on differ-
ent tissue types. In immune cells IL-4 has both potent
growth-stimulating and growth-inhibitory effects; how-
ever, in nonhematopoietic cells IL-4 has only growth-
inhibitory effects. The reason for the dichotomy is
unclear. Some of the differential effects may relate to
the signaling pathways used by IL-4Rα in different cell
types. It is possible that the presence of the IL-2R γ-
chain may be responsible for growth inhibition in some
nonhematopoietic cell lines by complexing through
JAK-1 and JAK-3/STAT (type I IL-4R) pathways,
whereas some other cells appear to respond even in the
absence of IL-2R γ-chain (type II IL-4R).20
The presence of IL-4Rα on NSCLC may relate to the
mechanism of development of lung cancers. Although
some studies suggest lung carcinomas arise from a sin-
Fig 8. JAK1 expression from NSCLC cell line LUst. Western blotting of untreated (—) and 500 U/mL IL-4–treat-
ed (+) LUst cell line demonstrated expression of the 130-kd JAK1 after immunoprecipitation with anti-IL-2R γ-
chain antibody. SK-MES-1 cell line demonstrated no evidence of JAK activation by means of IL-2R γ-
chain–induced binding.
gle common stem cell, the lack of IL-4Rα (and IL-2R
γ-chain) may represent an adaptive property of these
tumors to become autonomous from host growth-regu-
latory mechanisms. Often in the lung, mast cell and
CD4+ T-cell infiltrates are present adjacent to the tumor
infiltrate. Both of these cell types are known to produce
IL-4. The presence of IL-4Rα on NSCLC tumors may
represent a host defense mechanism that is lost during
tumor development.
The demonstration of functional IL-4Rα on tumor
cells suggests that a direct cytostatic effect may be pos-
sible. Either IL-4–directed treatment alone or treatment
conjugated to toxins may have a role in the treatment of
IL-4Rα+ lung carcinoma.30 On the other hand, the abil-
ity to induce G1-phase cell-cycle arrest in lung cancer
may be possible through replacement or reactivation of
the JAK-STAT pathway. Further understanding of the
mechanism of IL-4Rα signal transduction related to
cell growth may be beneficial in developing more
effective therapies for lung cancer.
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about 35% of cell lines and tumor biopsy specimens expressed
the IL-4R. We have seen upregulation of HLA-DR expression
by IL-4, but we did not further characterize this particular cell
line. In other words, we did not attempt to determine what
other tumor-associated markers are present on it.
Dr Rusch. It would be interesting to know what the rela-
tionship is between the IL-4 regulation in these cell lines and
other factors that are known to control the G1 to S transition
in most lung cancers, such as p53.
Dr Essner. We did not look specifically for p53 or cyclin
D1 regulation and so on, but certainly we could look at that.
We previously did some work with gastrointestinal cancers
and found that IL-4 upregulated unphosphorylated Rb protein
and downregulated cyclin D1, c-myc protein, and phosphory-
lated Rb protein.
Dr Rusch. How are you going to extend this work?
Dr Essner. The next question is whether we could in fact
take the SK-MES cell line and transfect it with the γ-chain
and see whether that reactivates cell cycle arrest. And the
other option, obviously, is to look at the LUst cell line and see
whether we can block the γ-chain and see whether this pre-
vents cell-cycle arrest induced by IL-4. We need to extend our
studies to other cell lines to see whether the same mechanism
is active and could be used for development of new therapies
for lung cancer.
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Discussion
Dr Valerie W. Rusch (New York, NY). Can you tell us a lit-
tle more about the cell lines that you used in terms of their
other molecular characteristics and how these are or are not
relevant to human tumors? 
Dr Essner. We used the LUst cell line, which is an adeno-
carcinoma established at UCLA. We found it to be the most
responsive to the effects of IL-4, and that is why we used it.
Our impression is that as cell lines undergo more and more
passages in culture, they lose the expression of the IL-4R and
become unresponsive to IL-4. LUst appears to retain expres-
sion of the IL-4R even after multiple passages in cell culture.
There have been some studies in the literature suggesting that
